Association of creatine kinase and skin toxicity in phase i trials of anticancer agents

British Journal of Cancer

Volumn 107, Issue 11, 2012, Pages 1797-1800

  Moreno Garcia, V ^a,b   Thavasu, P ^a,c   Blanco Codesido, M ^a,b   Molife, L R ^a,b   Vitfell Pedersen, J ^a,b   Puglisi, M ^a,b   Basu, B ^a,b   Shah, K ^a,b   Iqbal, J ^b   De Bono, J S ^a,b,c   Kaye, S B ^a,b,c   Banerji, U ^a,b,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

anticancer drug; creatine kinase; skin rash

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CREATINE KINASE; GEFITINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE;

ARTICLE; CELL STRESS; CREATINE KINASE BLOOD LEVEL; DRUG INDUCED DISEASE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KERATINOCYTE; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CREATINE KINASE; EXANTHEMA; HUMANS; KERATINOCYTES; RETROSPECTIVE STUDIES;

EID: 84870062182     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.482     Document Type: Article

References (20)

1. Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM (2010) The firstin-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16(5): 1613-1623
2. Caux F, Chosidow O, Philippon C, Roujeau JC, Revuz J (1994) Increased serum and blister fluid levels of creatine kinase in patients with toxic epidermal necrolysis. Br J Dermatol 130(3): 337-341
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9): 809-819
4. Gordon JK, Magid SK, Maki RG, Fleisher M, Berman E (2010) Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res 34(6): 827-829
5. Kiistala U, Paavonen T, Saarelainen I, Aronen H, Asko-Seljavaara S, Kariniemi AL, Ingervo L, Niemitalo S (1989) Epidermis is the origin of high creatine kinase levels in skin blister fluid. Acta Derm Venereol 69(4): 284-287
6. Knott A, Koop U, Mielke H, Reuschlein K, Peters N, Muhr GM, Lenz H, Wensorra U, Jaspers S, Kolbe L, Raschke T, Stab F, Wenck H, Gallinat S (2008) A novel treatment option for photoaged skin. J Cosmet Dermatol 7(1): 15-22
7. Kovesdi E, Luckl J, Bukovics P, Farkas O, Pal J, Czeiter E, Szellar D, Doczi T, Komoly S, Buki A (2010) Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir (Wien) 152(1): 1-17
8. Lenz H, Schmidt M, Welge V, Schlattner U, Wallimann T, Elsasser HP, Wittern KP, Wenck H, Stab F, Blatt T (2005) The creatine kinase system in human skin: protective effects of creatine against oxidative and UV damage in vitro and in vivo. J Invest Dermatol 124(2): 443-452
9. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15): 1960-1966
10. Moreno Garcia V, Baird RD, Shah KJ, Basu B, Tunariu N, Blanco M, Cassier PA, Pedersen JV, Puglisi M, Sarker D, Papadatos-Pastos D, Omlin AG, Biondo A, Ware JA, Koeppen H, Levy GG, Mazina KE, De Bono JS (2011) A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J Clin Oncol 29(15s): 199s (abstract no. 3021
11. Niklinski J, Furman M, Palynyczko Z, Laudanski J, Bulatowicz J (1991) Carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB as tumor markers for carcinoma of the lung. Neoplasma 38(6): 645-651
12. O'Donnell A, Faivre S, Burris III HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10): 1588-1595
13. Paavonen T, Aronen H, Saarelainen I, Neittaanmaki H, Hjelm I, Kiistala U (1988) The BB-isoenzyme is a major component of creatine kinase in skin blister fluid. Br J Dermatol 118(6): 753-757
14. Schlattner U, Mockli N, Speer O, Werner S, Wallimann T (2002) Creatine kinase and creatine transporter in normal, wounded, and diseased skin. J Invest Dermatol 118(3): 416-423
15. Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F (1992) Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage. Acta Neurochir (Wien) 115(3-4): 106-111
16. Stolcpart RS, Olson KL, Delate T, Rasmussen J, Rehring TF, Merenich JA (2010) The risk for significant creatine kinase elevation with statins. Am J Cardiovasc Drugs 10(3): 187-192
17. Stoyianni A, Kapodistrias N, Kampletsas E, Pentheroudakis G, Pavlidis N (2011) Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori 97(2): 252-255
18. Wallimann T, Tokarska-Schlattner M, Schlattner U (2011) The creatine kinase system and pleiotropic effects of creatine. Amino Acids 40(5): 1271-1296
19. Yap TA, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Tunariu N, Sullivan D, Yan L, De Bono JS, Tolcher AW (2010) First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. J Clin Oncol 28(15s): 235s (abstract no. 3009
20. Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis EP (1996) Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. Br J Cancer 73(3): 386-390